A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen". This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
There are three basic types of vaccines available: inactivated influenza vaccine (IIV), live attenuated influenza vaccine (LAIV), and recombinant influenza vaccines (RIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability. Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aminosalicylic acid | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Aminosalicylic acid. |
| Mesalazine | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Mesalazine. |
| Sulfasalazine | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Sulfasalazine. |
| Diflunisal | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Diflunisal. |
| Salicylic acid | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Salicylic acid. |
| Acetylsalicylic acid | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Acetylsalicylic acid. |
| Balsalazide | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Balsalazide. |
| Olsalazine | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Olsalazine. |
| Bismuth subsalicylate | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Bismuth subsalicylate. |
| Dersalazine | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Dersalazine. |
| Phenyl aminosalicylate | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Phenyl aminosalicylate. |
| Methyl salicylate | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Methyl salicylate. |
| Trolamine salicylate | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Trolamine salicylate. |
| Nitroaspirin | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Nitroaspirin. |
| Aloxiprin | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Aloxiprin. |
| Guacetisal | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Guacetisal. |
| Carbaspirin calcium | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Carbaspirin calcium. |
| Choline salicylate | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Choline salicylate. |
| Thiosalicylic acid | The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Thiosalicylic acid. |